Structure and procedures of the pharmacy and therapeutic committees in Spanish hospitals
- 253 Downloads
Objective Define the structure and working procedures of the Pharmacy and Therapeutic Committees (P&T Committees) in Spanish hospitals. Setting Hospitals over 75 beds located in all regions of the Spanish State. Method A cross-sectional descriptive study based on the completion of a questionnaire that consisted of 138 questions. The participants were recruited by post, e-mail and telephone between November 2007 and January 2008. The Hospitals were classified according to their size and public or private and university or non-university status. Main outcome measures They are related with the structure and composition of the P&T Committees, performance, drug evaluation process, working methods and the results of their activity. Results A total of 200 hospitals answered the questionnaire (response rate of 39.0% of hospitals and 57.1% of the beds in Spain). All the hospitals have P&T Committees, 99.5% have a Drug Formulary, 71.0% have a Therapeutic Interchange Programme and 91.0% have a document determining the mission, objectives and functions of the P&T Committee. Almost all hospitals (95.5%) have established a formal application for the inclusion of a drug in the hospital, while 80.5% have established a model for evaluation reports. The mean (SD) number of participants in P&T Committees was 11.84 (3.82). The annual mean of drugs evaluated per hospital was 10.35 (7.45). The proportion of assessments that concludes the inclusion, rejection or deferral of the decision was 75.3, 21.4 and 3.2%, respectively. Conclusion Spanish P&T Committees have a similar structure and function, a multi-disciplinary professional composition to carry out an important assessment activity. This activity is higher in large hospitals and in university hospitals. The proportion of the approved and rejected drugs is similar in different types of hospital. The Therapeutic Interchange Guidelines, the use of application models and the reports follow the indications of scientific collaborative groups, thus being used more in Spain than in other countries.
KeywordsData collection Decision-making Formularies Hospital Pharmacy and therapeutics committee Organizational Questionnaires Spain
T. Requena (Hospital Universitario La Paz. Madrid), J. P. Ordovás (Hospital General Universitario de Alicante), M. A. Porta (Hospital Universitario Juan Canalejo. La Coruña), J. M. Recalde (Centro Andaluz de Documentación e Información de Medicamentos. Granada), C. Calvo (Servicio de Salud de Illes Balears. Palma de Mallorca), E. Corpas, L. García-Mochón and M. Moya (Escuela Andaluza de Salud Pública. Granada).
This study was supported by the Carlos III Health Institute (Instituto de Salud Carlos III), Ministry of Health and Social Policy in Spain.
Conflicts of interest
The authors declare that they have no conflicts of interest.
- 12.Spanish Ministry of Health and Social Policy. Spanish Government. SNS Primary Care Centres Records and the Nacional Hospital Records (internet database). Madrid. Ministry of Health and Social Policy, 2007. 20 July 2010. Available from: http://www.msps.es/ciudadanos/prestaciones/centrosServiciosSNS/hospitales/home.htm.
- 13.Santos B, Flores S, Briones E, Marín R, Gallego S, Bautista FJ. Update of the guide for the introduction of new drugs. Andalusian Agency for Health Technology Assessment, Seville. Reports, studies and research. Edited by the Spanish Ministry of Health and Consumer Affairs. Madrid (Spain), 2007. 20 July 2010. Available from: http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/AETSA_2006_03_GINF.pdf.
- 15.Group for Innovation Assessment, Standardisation and Research in the Selection of Drugs (GENESIS) of the Spanish Association of Hospital Pharmacy. Madre Programme. Procedures Manual. PDF 3.0 version. September 2005. 20 July 2010. Available from: http://genesis.sefh.es/basesmetodologicas/programamadre/index.html.
- 18.Delgado O, Puigventós F, Llodrá V, Comas F, Cervera M, Sánchez A, et al. Program for the substitution of therapeutic equivalents in the hospital setting. Rev Clin Esp. 2000;200:261–70.Google Scholar
- 20.Peris JF, Faus VJ, de la Vega A, Martines G, Martínez MA. Therapeutic interchange between angiotensin II receptor blockers in institutionalized elderly patients: implementing a protocol. Farm Hosp. 2003;27:290–7.Google Scholar
- 21.Navarro S, Font I, Lerma E, López E, Martínez MJ, Poveda JL. Therapeutic interchange of drugs not included in the hospitals pharmacotherapeutic guide: a quality programme. Farm Hosp. 2004;28:266–74.Google Scholar
- 23.Crespí M, Delgado O, Ventayol P, Lafuente A, Pinteño M, Escrivá A, et al. A prospective randomized study of sulphonylureas therapeutic interchange in patients with type 2 diabetes mellitus. Farm Hosp. 2004;28:426–32.Google Scholar
- 24.Alós M, Mangues MA, Santos-Ramos B. Spanish presence in BPS accreditation. Farm Hosp. 2010. doi: 10.1016/j.farma.2010.01.003.
- 26.Australian Government. Department of Health and Ageing. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee [Internet]. 20 July 2010. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-pubs-pharmpac-gusubpac.htm.